|
|
Article: Pentose Reports New Preclinical Data on INACTINE(TM) for Ex Vivo Viral Inactivation of Red Blood Cells for Transfusion.
- Article from:
- PR Newswire
- Article date:
- November 2, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Red Blood Cell and Plasma Derivative Data Presented at 51st Annual Meeting of
American Association of Blood Banks
PHILADELPHIA, Nov. 2 /PRNewswire/ -- Pentose Pharmaceuticals, Inc. today reported new data on the viral inactivation abilities of its proprietary INACTINE(TM) technology that destroys both enveloped and non-enveloped viruses in red blood cell concentrates and plasma-derived therapeutic proteins without affecting their integrity. The data were presented at the 51st Annual Meeting of the American Association of Blood Banks (AABB) held October 31 - November 4, 1998.
"Currently there are no effective technologies available to ...